Login to Your Account



Tigenix hands off Chondrocelect rights to Sobi in cash-free deal

By Cormac Sheridan
Staff Writer

Thursday, April 3, 2014
Tigenix NV has thrown in the towel on its efforts to obtain broad reimbursement in Europe for its Chondrocelect autologous cell therapy for regenerating cartilage in the knee and has signed over marketing and distribution rights to Swedish Orphan Biovitrum AB (Sobi) in return for double-digit sales royalties.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription